SecBot SecBot
SECBOTREPLAY Home › Report › CLDX

CLDX · Celldex Therapeutics is conducting a follow-on public offering of…

Celldex Therapeutics, Inc. · 424B5 filed Apr 1, 2026 at 16:07 ET

At the news

NEUTRALIMPACT 5/10

424B5 filed Apr 1, 2026 at 16:07 ET

Celldex Therapeutics is conducting a follow-on public offering of common stock to raise capital. The proceeds will fund commercial readiness for barzolvolimab, clinical development of its pipeline, and general corporate purposes. The offering represents dilution to existing shareholders and is being conducted at a time when the company has no commercial revenue and relies on capital markets for funding.

  • Celldex Therapeutics (CLDX) is conducting a follow-on public offering of common stock.
  • The offering is priced at $31.72 per share, the last reported sale price on March 31, 2026.
  • Net proceeds, estimated at approximately $ million (before expenses), will be used for commercial readiness of barzolvolimab, clinical development, and general corporate purposes.
  • The company has granted underwriters a 30-day option to purchase up to an additional 15% of shares.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access